- Raised $30M funding round, Jan 2022
- Raised $12M funding round, Jan 2012
- Raised $500k funding round, May 2006
About
Mirror Biologics is an international biopharmaceutical company specialized in development and manufacturing of next generation immunotherapy products where the active ingredients are living immune cells. Its technology originally spun out from Hadassah-Hebrew University Medical Center in Jerusalem. The company operates a 21 CFR 1271-compliant blood donor and cell processing center and conduct research and development on the design and testing of novel bioreactors and commercial manufacturing systems.
Its next generation immunotherapy programs aim to harness the power of the human immune system to treat and prevent disease. The company has developed a patented immune cell, called AlloStim®, with powerful immunomodulatory properties that is used to educate and modify a patients’ own immune system to enable it to identify and destroy cancers and infectious organisms and to reprogram immune systems weakened by age or chronic infection.
Its immunomodulatory vaccine development programs are based upon its novel Mirror Effect® technology platform which is able to imprint a re-programmed immune response over an existing failed immune response of a diseased or elderly patient. This novel technology platform expands the indications and type of patients that might benefit from immunotherapy approaches beyond first generation CAR-T and checkpoint inhibitor approaches.
Mirror Biologics acquired all the assets of Immunovative Therapies.
Funding history · 3 rounds · $42.5M total
Q&A
- What is Mirror Biologics' primary focus?
- Mirror Biologics is an international biopharmaceutical company specializing in the development and manufacturing of next-generation immunotherapy products, with active ingredients being living immune cells.
- When was Mirror Biologics founded?
- Mirror Biologics was founded in May 2004.
- What is the total amount of funding Mirror Biologics has raised to date?
- Mirror Biologics has raised a total of $42,500,000 USD.
- What was Mirror Biologics' most recent funding round?
- Mirror Biologics completed a funding round in January 2022, raising $30,000,000 USD.
- How many employees does Mirror Biologics currently have?
- Mirror Biologics has 1-10 employees.
- What is the name of Mirror Biologics' patented immune cell technology?
- Mirror Biologics has developed a patented immune cell called AlloStim®, which possesses powerful immunomodulatory properties.
- Where is Mirror Biologics headquartered?
- Mirror Biologics is headquartered in Jerusalem, Israel.
- What is Mirror Biologics' core technology platform for vaccine development?
- Mirror Biologics' immunomodulatory vaccine development programs are based on its novel Mirror Effect® technology platform.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | mirrorbio.com/ |
|---|---|
| linkedin.com/company/13180493 |
Identifiers & details
| Former names | Immunovative Therapies |
|---|---|
| Founded | 2004-5 |
| Employees (exact) | 9 |
| Offices | Tampa; Malaysia; Bangkok |
Radar intelligence
Patents
| EPO | 13 |
|---|
Web history (Wayback)
| Domain | mirrorbio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 6 |
|---|